Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease

Nephron - Clinical Practice

Volumn 113, Issue 1, 2009, Pages

  Paragh, Gyorgy ^a   Seres, Ildiko ^a   Harangi, Mariann ^a   Pocsai, Zsuzsa ^a   Asztalos, Laszlo ^a   Locsey, Lajos ^b   Szeles, Gyorgy ^a   Kardos, Laszlo ^a   Varga, Eva ^a   Karpati, Istvan ^a   Adany, Roza ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Kenezy Hospital   (Hungary)

Author keywords

Dyslipidemia; Genotype; Paraoxonase; Phenotype; Renal failure; Renal transplantation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHRONIC DISEASE; CREATININE; FEMALE; GENOTYPE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; UREA; YOUNG ADULT;

EID: 67650110146     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228075     Document Type: Article

References (27)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112-S119. (Pubitemid 28527268)
2. Mackness B, Durrington PN, Macness MI: Human serum paraoxonase. Gen Pharmacol 1998;31:329-336.
3. La Du BN, Eckerson HW: The polymorphic paraoxonase/aryl-esterase isoenzymes of human serum. Fed Proc 1984;43:2338-2341. (Pubitemid 14107564)
4. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082-2088. (Pubitemid 28482156)
5. Dirican M, Akca R, Sarandol E, Dilek K: Serum paraoxonase activity in uremic predialysis and haemodialysis patients. J Nephrol 2004;17:813-818. (Pubitemid 41158301)
6. Gülcin A, Özgönül M, Sözmen EZ, Aslan SL, Sözmen B: Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol 2002;15:144-149.
7. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS: Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998;44:179-181. (Pubitemid 28042485)
8. Itahara T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon Y, Kawada M, Hashimoto K: Serum paraoxonase and aryl-esterase activities in haemodialysis patients. J Atheroscler Thromb 2000;7:152-158.
9. Paragh G, Asztalos L, Seres I, Balogh Z, Löcsey L, Kárpáti I, Mátyus J, Katona E, Harangi M, Kakuk G: Serum paraoxonase activity changes in uremic and kidney transplanted patients. Nephron 1999;83:126-131. (Pubitemid 29447506)
10. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G: Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71-80. (Pubitemid 26101430)
11. Schiavon R, Battaglia P, De Fanti E, Fasolin A, Biasioli S, Targa L, Guidi G: HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002;324:39-44. (Pubitemid 35245493)
12. Suehiro T, Ikeda Y, Shiinoki T, Kumon Y, Ithara T, Hasimoto K: Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002;9:133-138.
13. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G: Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008;41:381-386.
14. Dirican M, Sarandol E, Serdar Z, Ocak N, Dilek K: Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis. Clin Nephrol 2007;68:144-150. (Pubitemid 47381200)
15. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, Arii K, Hashimoto K: Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007;67:358-365. (Pubitemid 46894800)
16. Vincent-Viry M, Sass C, Bastien S, Aguillon D, Siest G, Visvikis S: PON1-192 phenotype and genotype assessments in 918 subjects of the Stanislas Cohort Study. Clin Chem Lab Med 2003;41:535-540. (Pubitemid 36592121)
17. Szeles G, Voko Z, Jenei T, Kardos L, Pocsai Z, Bajtay A, Papp E, Pásti G, Kósa Z, Molnár I, Lun K, Adány R: A preliminary evaluation of a health monitoring programme in Hungary. Eur J Public Health 2005;15:26-32. (Pubitemid 40490701)
18. Pocsai Z, Toth Z, Paragh G, Szeles G, Adany R: Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clin Chim Acta 2003;33:231-236. (Pubitemid 36577486)
19. Akhmedova SN, Yakimovsky AK, Schwartz EI: Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001;184:179-182. (Pubitemid 32178272)
20. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-1457.
21. Brophy V, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE: Promoter polymorphism effects on paraoxonase (PON1) expression. Am J Hum Genet 2001;68:1428-1436.
22. Covic A, Gusbeth-Tatomir P, Goldsmith DJA: The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 2003;16:476-486. (Pubitemid 38120457)
23. Kalogerakis G, Baker AM, Chrisov S, Rowley KG, Dwyer K, Winterbourn C, Best JD, Jenkins AJ: Oxidative stress and high-density lipoprotein function in type I diabetes and end-stage renal disease. Clin Sci 2005;108:497-506. (Pubitemid 40827557)
24. van Himbergen TM, Roest M, de Graaf J, Jansen EH, Hattori H, Kastelein JJ, Voorbij HA, Stalenhoef AF, van Tits LJ: Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005;46:445-451. (Pubitemid 43109780)
25. Agachan B, Yimlaz H, Isbir T, Akoglu E: Paraoxonase 192 polymorphism and its relationship to serum lipids in Turkish renal transplant recipients. Transplant Proc 2004;36:1385-1386. (Pubitemid 38902983)
26. Abraham P, Sugumar E: Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stress. Arch Toxicol 2008;82:237-238. (Pubitemid 351661648)
27. Roest M, van Himbergen TM, Barendrecht AB, Peeters PHM, van der Schouw YT, Voorbij HAM: Genetic and environmental determinants of the PON-I phenotype. Eur J Clin Invest 2007;37:187-196. (Pubitemid 46310581)